Seneca valley virus (SVV) cellular receptor targeted oncotherapy
Inventors
MILES, Linde • POIRIER, John • RUDIN, Charles
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12472218-B2
Publication Date
2025-11-18
Expiration Date
Abstract
A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a cancer patient with SVV is disclosed.
Core Innovation
The invention relates to Seneca Valley Virus (SVV), a SVV mutant or a SVV variant, and selecting a cancer patient for treatment using a predictive biomarker strategy based on anthrax toxin receptor 1 (ANTXR1). A subject is selected when cancerous tissue shows a normal expression level or an elevated expression level of ANTXR1, together with decreased expression level of a biomarker of the α-interferon or β-interferon pathway.
The invention addresses the problem of identifying which cancer patients will have SVV permissivity, where SVV permissivity is linked to ANTXR1 as the essential SVV receptor. The document states that SVV permissivity requires reduced innate immune or IFN signaling in addition to ANTXR1 being normal or elevated, and it ties SVV permissivity to interferon pathway biomarker expression levels.
The invention includes a matching diagnostic/selection kit concept for detecting expression levels of ANTXR1 and expression levels of one or more α-interferon or β-interferon pathway biomarkers, together with instructions to select a cancer patient for treatment with SVV, a SVV mutant or a SVV variant. Supporting context in the document reports that ANTXR1 loss abolishes SVV permissivity and binding, ANTXR1 re-expression rescues permissivity, and SVV directly interacts with ANTXR1 while interferon pathway activation reduces SVV permissivity.
Claims Coverage
The provided claim set contains one independent claim covering a patient-selection kit for SVV (including SVV mutants/variants), using detection of ANTXR1 expression together with detection of α-interferon and/or β-interferon pathway biomarker expression, for selecting a subject with cancerous tissue having normal/elevated ANTXR1 and decreased interferon-pathway biomarker expression. The dependent claims refine the ANTXR1 detection reagent and specify an SVV composition member.
Patient selection kit using ANTXR1 and interferon pathway biomarker expression
A kit for selecting a cancer patient for treatment with Seneca Valley Virus (SVV), a SVV mutant or a SVV variant, comprising reagents for detecting an expression level of anthrax toxin receptor 1 (ANTXR1), a reagent for detecting expression levels of one or more biomarkers of the α-interferon or β-interferon pathway, and instructions to select a cancer patient for treatment when cancerous tissue has a normal or elevated ANTXR1 expression level and a decreased expression level of an α-interferon or β-interferon pathway biomarker.
Anti-ANTXR1 antibody detection reagent
The kit further includes a reagent comprising an anti-ANTXR1 antibody for detecting the expression level of ANTXR1.
ANTXR1-specific oligonucleotide primers for detecting ANTXR1 expression
The kit further includes, for detecting ANTXR1 expression level, a reagent comprising ANTXR1-specific oligonucleotide primers selected from specified SEQ ID NO pairs.
SVV composition including SVV-001
The kit further specifies that the SVV includes SVV-001.
Across the independent and dependent claims provided, the inventive concept is a selection kit that uses ANTXR1 expression (normal or elevated) together with decreased α-/β-interferon pathway biomarker expression to select cancer patients for SVV treatment, with refinements for the ANTXR1 detection reagent modality and an SVV composition member.
Stated Advantages
Documented Applications
No documented applications found
Interested in licensing this patent?